Respiratory (Asthma)


TARGET-ASTHMA will capture important data on patients with asthma in the real world. This will not only aid in mapping the natural history of asthma but will also provide insights into the impact of different treatment paradigms on patient populations over time and collect real-world data as new agents are proceeding to market. Michael Wechsler, MD, MMSc

Asthma is a chronic inflammatory disease of the respiratory tract that affects over 25 million people in the United States alone, including 5 million children. Patients with uncontrolled asthma contribute to high health care costs, often needing emergency department visits and hospitalizations. There is a corresponding need for real-world, longitudinal data evaluating this disease.

TARGET-ASTHMA is a longitudinal study of participants being treated for asthma and captures additional respiratory diseases extending 3-years retrospectively before patient consent and up to 10-years prospectively. This dataset provides partners with immediate access to real-world data which can be utilized to evaluate effectiveness and safety data for new drug approvals.

The TARGET-ASTHMA platform includes meticulously curated structured and unstructured data from medical records and patient-reported outcome measures and collects biospecimen samples. Partners can utilize the data to support their drug development and commercialization processes, review optimal treatment approaches, reduce time and costs of conducting post-marketing surveillance, answer critical real-world comparative safety/effectiveness questions and conduct pharmacology studies to determine targeted customers for future clinical trials.

Study Goals:

  • Explore the safety and effectiveness of all current and future therapies utilized in typical clinical practice across diverse populations

  • Analyze populations underrepresented in phase III clinical trials

  • Assess optimal duration, timing, sequence and combination of asthma therapies to achieve clinical response and remission

  • Understand bronchoscopy outcomes

  • Estimate adverse event frequency/severity and describe management practices

  • Evaluate outcomes related to enrollment and utilization of patient support programs (PSPs)


February 2020


Enrollment Goal:

Up to 10,000

TARGET-ASTHMA Steering Committee

Michael E. Wechsler, MD, MMSc (Chair)
Professor and Director of the Cohen Family Asthma Institute, Denver, CO

Monica Kraft, MD
Professor and Chair of the Department of Medicine, Tucson, AZ

Interested in launching a new disease registry?

Target RWE has developed a turnkey solution to rapidly activate disease agnostic registries to support partners.